Losartan and tempol treatments normalize the increased response to hydrogen peroxide in resistance arteries from hypertensive rats

Journal of Hypertension

Volumn 27, Issue 9, 2009, Pages 1814-1822

  García Redondo, Ana B ^a   Briones, Ana M ^a   Avendaño, María S ^a   Hernanz, Raquel ^b   Alonso, María J ^b   Salaices, Mercedes ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Angiotensin II; Hydrogen peroxide; Hypertension; Nitric oxide; Resistance arteries

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; HYDROGEN PEROXIDE; LOSARTAN; NITRIC OXIDE; NITRITE; SUPEROXIDE; TEMPOL; THROMBOXANE A2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HYPERTENSION; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

EID: 73249116181     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832d23e6     Document Type: Article

References (40)

1. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008; 31:S170-S180.
2. Lacy F, Kailasam MT, O'Connor DT, Schmid-Schönbein GW, Parmer RJ. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension 2000; 36:878-884. (Pubitemid 30943751)
3. Dikalov SI, Dlkalova AE, Bikineyeva AT, Schmidt HH, Harrison DG, Griendling KK. Distinct roles of Nox1 and Nox4 in basal and angiotensin IIstimulated superoxide and hydrogen peroxide production. Free Radie Biol Med 2008; 45:1340-1351.
4. Olson JS, Bailou DP, Palmer G, Massey V. The mechanism of action of xanthine oxidase. J Biol Chem 1974; 249:4363-4382.
5. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91:406-413. (Pubitemid 35034208)
6. - levels. J Pharmacol Exp Ther 2009; 328:19-27.
7. Ardanaz N, Pagano PJ. Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp Biol Med (Maywood) 2006; 231:237-251. (Pubitemid 43334308)
8. Rodríguez-Martínez MA, Garcia-Cohen EC, Baena AB, González R, Salaices M, Marin J. Contractile responses elicited by hydrogen peroxide in aorta from normotensive and hypertensive rats. Endothelial modulation and mechanism involved. Br J Pharmacol 1998; 125:1329-1335. (Pubitemid 28542544)
9. 2 production. Br J Pharmacol 2001; 134:1639-1646.
10. Ruiz-Ortega M, Esteban V, Rupérez M, Sánchez-López E, Rodríguez-Vita J, Carvajal G, Egido J. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens 2006; 15:159-166. (Pubitemid 43755821)
11. Virdis A, Colucci R, Fornai M, Duranti E, Giannarelli C, Bernardini N, et al. Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin ll-infused mice. Hypertension 2007; 49:679-686. (Pubitemid 46263213)
12. Ohnaka K, Numaguchi K, Yamakawa T, lnagami T. Induction of cyclooxygenase-2 by angiotensin II ¡cultured rat vascular smooth muscle cells. Hypertension 2000; 35:68-75. (Pubitemid 30054239)
13. Alvarez Y, Pérez-Girón JV, Hernanz R, Briones AM, Garcia-Redondo A, Beltrán A, et al. Losartan reduces the increased participation of cyclooxygenase-2-derived products in vascular responses of hypertensive rats. J Pharmacol Exp Ther 2007; 321:381-388. (Pubitemid 46456962)
14. Beltrán AE, Briones AM, García-Redondo AB, Rodríguez C, Miguel M, Alvarez Y, et al. p38 MAPK contributes to angiotensin ll-induced COX-2 expression in aortic fibroblasts from normotensive and hypertensive rats. J Hypertens 2009; 27:142-154.
15. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977; 41:19-26. (Pubitemid 8132079)
16. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001 ; 5:62-71. (Pubitemid 34146173)
17. Jíménez-Altayó F, Bríones AM, Gíraldo J, Planas AM, Salaices M, Víla E. Increased superoxide anion production by interleukin-1β impairs nitric oxide-mediated relaxation in resistance arteries. J Pharmacol Exp Ther 2006; 316:42-52. (Pubitemid 41832579)
18. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin ll-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97:1916-1923. (Pubitemid 26129879)
19. 2 in vascular smooth-muscle cells. Biochem J 1994; 299:197-201.
20. Jaimes EA, Zhou MS, Pearse DD, Puzis L, Raij L. Upregulatlon of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species. Am J Physiol Renal Physiol 2008; 294:F385-392.
21. LyleAN, Griendling KK. Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology (Bethesda) 2006; 21:269-280. (Pubitemid 44156859)
22. Donmez G, Derici U, Erbas D, Arinsoy T, Onk A, Sindel S, Hasanoglu E. The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essential hypertension. Jpn J Physiol 2002; 52:435-440. (Pubitemid 36205587)
23. Polizio AH, Peña C. Effects of angiotensin II type 1 receptor blockade on the oxidative stress in spontaneously hypertensive rat tissues. Regul Pept 2005; 128:1-5. (Pubitemid 40255528)
24. Le Marquer-Domagala F, Finet M. Comparison of the nitric oxide and cyclooxygenase pathway in mesenteric resistance vessels of normotensive and spontaneously hypertensive rats. Br J Pharmacol 1997; 121:588-594. (Pubitemid 27226314)
25. Briones AM, Alonso MJ, Marin J, Balfagón G, Salaices M. Influence of hypertension on nitric oxide synthase expression and vascular effecfs of lipopolysaccharlde in rat mesenteric arteries. Br J Pharmacol 2000; 131:185-194. (Pubitemid 30768115)
26. Budzyn K, Ravi RM, Miller AA, Sobey CG. Mechanisms of augmented vasoconstriction induced by 5-hydroxytryptamine in aortic rings from spontaneously hypertensive rats. Br J Pharmacol 2008; 155:210-216.
27. Wiggers GA, Pecanha FM, Briones AM, Pérez-Girón JV, Miguel M, Vassallo DV, et al. Low mercury concentrations cause oxidative stress and endothelial dysfunction in conductance and resistance arteries. Am J Physiol Heart Circ Physiol 2008; 295:H1033-H1043.
28. Tschudi MR, Mesaros S, Luscher TF, Malinski T. Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension. Hypertension 1996; 27:32-35. (Pubitemid 26017677)
29. Kung CF, Luscher TF. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 1995; 25:194-200.
30. Schulz E, Jansen T, Wenzel P, Daiber A, Munzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008; 10:1115-1126.
31. Marin J, Rodríguez-Martinez MA. Role of vascular nitric oxide in physiological and pathological conditions. Pharmacol Ther 1997; 75:111-134. (Pubitemid 27521027)
32. Landmesser U, Drexler H. Endothelial function and hypertension. CurrOpin Cardiol 2007; 22:316-320.
33. Maeso R, Rodrigo E, Muñoz-García R, Navarro-Cid J, Ruilope LM, Cachofeiro V, Lahera V. Factors involved in the effects of losartan on endothelial dysfunction induced by aging in SHR. Kidney Int Suppl 1998; 68:S30-35.
34. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide In patients with coronary artery disease: role of superoxide dismutase. Circulation 2001 ; 103:799-805. (Pubitemid 32163876)
35. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC. Longterm antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001 ; 37:781-786. (Pubitemid 32199066)
36. Yanes L, Romero D, lliescu R, Cucchiarelli VE, Fortepiani LA, Santacruz F, et al. Systemic arterial pressure response to two weeks of tempol therapy in SHR: involvement of NO, the RAS, and oxidative stress. Am J Physiol Regul lntegr Comp Physiol 2005; 288:R903-R908.
37. Grote K, Ortmann M, Salguero G, Doerries C, Landmesser U, Luchtefeld M, etal. Critical role for p47phox in renin-angiotensin system activation and blood pressure regulation. Cardiovasc Res 2006; 71:596-605. (Pubitemid 44107869)
38. Preti SC, da Cunha V, Vassallo DV, Stefanon I. The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. Basic Clin Pharmacol Toxicol 2005; 97:29-34. (Pubitemid 40896818)
39. Frisbee JC. Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome. Am J Physiol Regul lntegr Comp Physiol 2005; 289:R307-R316.
40. Thengchaisri N, Kuo L Hydrogen peroxide induces endotheliumdependent and -independent coronary arteriolar dilation: role of cyclooxygenase and potassium channels. Am J Physiol Heart Circ Physiol 2003; 285:H2255-2263.